Hematologic Malignancy
B-Cell Neoplasm
CI-CAN-00000470Explore in graph →
HematologicNon-malignant2,098 active trials46 approved drugs301 evidence items
- NCIt
- C27907
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000470Explore in graph →
Clinical trials
7,503 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01556438 | Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma | completed | Phase 1 | 16 | Eli Lilly and CompanyINDUSTRY | 1 | Mar 20, 2019 | clinicaltrials |
| NCT00724971 | Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab | completed | Phase 1 | 10 | PfizerINDUSTRY | 1 | Mar 15, 2019 | clinicaltrials |
| NCT01370694 |
| Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001) |
| terminated |
| Phase 1 |
| 7 |
| Merck Sharp & Dohme LLCINDUSTRY |
| 0 |
| Mar 15, 2019 |
| clinicaltrials |
| NCT02497378 | A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 8 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Mar 7, 2019 | clinicaltrials |
| NCT00520130 | Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System | completed | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2019 | clinicaltrials |
| NCT00648739 | Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM | terminated | Phase 1 / Phase 2 | 26 | Alexion Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 5, 2019 | clinicaltrials |
| NCT02745769 | A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents | completed | Phase 1 | 23 | Eli Lilly and CompanyINDUSTRY | 3 | Mar 5, 2019 | clinicaltrials |
| NCT01440582 | Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients | completed | Phase 1 | 77 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 4, 2019 | clinicaltrials |
| NCT02549651 | MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023) | completed | Phase 1 | 32 | MedImmune LLCINDUSTRY | 4 | Feb 27, 2019 | clinicaltrials |
| NCT02652910 | Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma(MeCAR) | unknown | Phase 1 / Phase 2 | 20 | Xinqiao Hospital of ChongqingOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT03093168 | BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma | unknown | Phase 1 | 10 | The Second Affiliated Hospital of Henan University of Traditional Chinese MedicineOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT03854994 | CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia | unknown | Phase 1 | 10 | Yan'an Affiliated Hospital of Kunming Medical UniversityOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT02842138 | Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma | unknown | Phase 1 | 25 | Peking UniversityOTHER | 1 | Feb 25, 2019 | clinicaltrials |
| NCT01403246 | Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With Chronic Lymphocytic Leukemia (CLL) | terminated | Phase 1 / Phase 2 | 9 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Feb 12, 2019 | clinicaltrials |
| NCT02679196 | The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma | completed | Phase 1 | 23 | Karus Therapeutics LimitedINDUSTRY | 1 | Feb 6, 2019 | clinicaltrials |
| NCT00943319 | Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies | completed | Phase 1 / Phase 2 | 50 | University of ChicagoOTHER | 1 | Feb 4, 2019 | clinicaltrials |
| NCT03379493 | Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma | terminated | Phase 1 | 4 | Eureka Therapeutics Inc.INDUSTRY | 1 | Feb 4, 2019 | clinicaltrials |
| NCT03060850 | A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL | unknown | Phase 1 | 184 | Hangzhou ACEA Pharmaceutical Research Co., Ltd.INDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT01897012 | Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas | completed | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Jan 28, 2019 | clinicaltrials |
| NCT02611908 | Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib. | withdrawn | Phase 1 | 0 | Michael ChoiOTHER | 0 | Jan 25, 2019 | clinicaltrials |
| NCT00727415 | Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to Therapy(LLC0606) | completed | Phase 1 / Phase 2 | 42 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 22, 2019 | clinicaltrials |
| NCT01634217 | Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation | completed | Phase 1 | 16 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 18, 2019 | clinicaltrials |
| NCT02976857 | A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects(C-CAR011) | completed | Phase 1 | 15 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Jan 17, 2019 | clinicaltrials |
| NCT01549431 | Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma | completed | Phase 1 | 32 | Emory UniversityOTHER | 1 | Jan 16, 2019 | clinicaltrials |
| NCT03132584 | Cyclophosphamide and Alemtuzumab In Lymphoma | terminated | Phase 1 | 3 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 14, 2019 | clinicaltrials |
| NCT01892293 | CT Antigen TCR-Engineered T Cells for Myeloma | terminated | Phase 1 / Phase 2 | 6 | AdaptimmuneINDUSTRY | 1 | Jan 10, 2019 | clinicaltrials |
| NCT01303965 | Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM) | terminated | Phase 1 / Phase 2 | 14 | Sherif S. FaragOTHER | 1 | Jan 8, 2019 | clinicaltrials |
| NCT02240719 | Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer | completed | Phase 1 | 20 | University of California, DavisOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT02454270 | A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies | terminated | Phase 1 | 59 | Janssen Research & Development, LLCINDUSTRY | 5 | Dec 20, 2018 | clinicaltrials |
| NCT01292603 | A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia | completed | Phase 1 | 240 | Hoffmann-La RocheINDUSTRY | 19 | Dec 19, 2018 | clinicaltrials |
| NCT03591744 | Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT00073749 | Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma | completed | Phase 1 | 79 | PfizerINDUSTRY | 7 | Dec 17, 2018 | clinicaltrials |
| NCT03672253 | CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma | unknown | Phase 1 | 20 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Dec 14, 2018 | clinicaltrials |
| NCT03674463 | LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma | unknown | Phase 1 | 10 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Dec 14, 2018 | clinicaltrials |
| NCT03349346 | Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents | withdrawn | Phase 1 | 0 | Gilead SciencesINDUSTRY | 4 | Dec 11, 2018 | clinicaltrials |
| NCT03757000 | A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies | unknown | Phase 1 | 42 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | Dec 10, 2018 | clinicaltrials |
| NCT03767725 | Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma | unknown | Phase 1 | 10 | Shenzhen Second People's HospitalOTHER | 1 | Dec 10, 2018 | clinicaltrials |
| NCT03685786 | CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT | unknown | Phase 1 | 20 | Shenzhen Second People's HospitalOTHER | 1 | Dec 7, 2018 | clinicaltrials |
| NCT03767751 | A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 80 | Chinese PLA General HospitalOTHER | 1 | Dec 7, 2018 | clinicaltrials |
| NCT03346642 | Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Dec 3, 2018 | clinicaltrials |
| NCT03366324 | Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies | unknown | Phase 1 / Phase 2 | 20 | Wuhan Sian Medical Technology Co., LtdINDUSTRY | 1 | Nov 20, 2018 | clinicaltrials |
| NCT01306643 | Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma | completed | Phase 1 / Phase 2 | 18 | Gilead SciencesINDUSTRY | 1 | Nov 19, 2018 | clinicaltrials |
| NCT01645930 | Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 | 43 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | Nov 8, 2018 | clinicaltrials |
| NCT00790842 | Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction(PrE1003) | terminated | Phase 1 / Phase 2 | 63 | PrECOG, LLC.OTHER | 1 | Oct 24, 2018 | clinicaltrials |
| NCT01342289 | Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide | completed | Phase 1 | 127 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 17, 2018 | clinicaltrials |
| NCT03706547 | Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM | unknown | Phase 1 | 20 | Peng LiuOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT02075021 | Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma(rev/abraxane) | terminated | Phase 1 / Phase 2 | 3 | NYU Langone HealthOTHER | 1 | Oct 15, 2018 | clinicaltrials |
| NCT00231166 | Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma | completed | Phase 1 | 33 | Novartis PharmaceuticalsINDUSTRY | 2 | Oct 11, 2018 | clinicaltrials |
| NCT02055924 | Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas(BIBLOS) | terminated | Phase 1 | 85 | The Lymphoma Academic Research OrganisationOTHER | 2 | Oct 11, 2018 | clinicaltrials |
| NCT00024466 | Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 28 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 19, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Mar 20, 2019source: clinicaltrials